DNA vaccines for biodefense

Abstract

An ideal biodefense vaccine platform would allow for the quick formulation of novel vaccines in response to emerging or engineered pathogens. The resultant vaccine should elicit protective immune responses in one to three doses and be unaffected by pre-existing immunity to vaccine components. In addition, it should be amenable to combination and multi-agent formulation, and should be safe for all populations and the environment. DNA vaccines can potentially meet all of these requirements; thus, this platform is being tested with several biodefense threats. Here, we provide a review of the current status of the development efforts for DNA vaccines against several relevant biodefense pathogens: Bacillus anthracis, Ebola and Marburg viruses, smallpox virus, and Venezuelan equine encephalitis virus.

Keywords::

• alphavirus
• anthrax
• Bacillus anthracis
• biodefense
• DNA vaccine
• Ebola virus
• electroporation
• gene gun
• Marburg virus
• monkeypox virus
• poxvirus
• smallpox
• vaccinia virus
• variola virus
• Venezuelan equine encephalitis virus

Disclaimer

The opinions, interpretations, conclusions and recommendations contained herein are those of the authors and are not necessarily endorsed by the US Army.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.